Enovis Corporation (ENOV) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$24.85
Price Target
$46.60
Target Range
$40.00 — $52.00
Analyst Rating
Buy
Forward P/E6.9x
Trailing P/E-1.2x
Forward PEG—
Implied Growth+117.2%
Median Target$50.00
Analyst Spread25.8%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$40
+61.0%
Consensus
$47
+87.5%
Bull Case
$52
+109.3%
ENOV Price Target Analysis
Updated May 7, 2026As of May 7, 2026, Enovis Corporation (ENOV) has a Wall Street consensus price target of $46.60, based on estimates from 13 covering analysts. With the stock currently trading at $24.85, this represents a potential upside of +87.5%. The company has a market capitalization of $1.42B.
Analyst price targets range from a low of $40.00 to a high of $52.00, representing a 26% spread in expectations. The median target of $50.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 10 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ENOV trades at a trailing P/E of -1.2x and forward P/E of 6.9x. Analysts expect EPS to grow +117.2% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Industrials stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+39.3%
Avg Forward P/E72.6x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HOLXHologic, Inc. | $17.0B | $76.01 | $79.00 | +3.9% | Hold | 17.2x | 42 |
 NVCRNovoCure Limited | $1.9B | $16.50 | $33.50 | +103.1% | Buy | — | 15 |
 INVAInnoviva, Inc. | $1.9B | $22.52 | $37.67 | +67.3% | Buy | 11.8x | 10 |
 LMATLeMaitre Vascular, Inc. | $2.5B | $110.22 | $101.50 | -7.9% | Buy | 38.0x | 20 |
 ATRCAtriCure, Inc. | $1.4B | $28.01 | $50.67 | +80.9% | Buy | 373.5x | 19 |
 ZBHZimmer Biomet Holdings, Inc. | $16.2B | $82.83 | $97.90 | +18.2% | Hold | 9.8x | 42 |
 SNNSmith & Nephew plc | $12.8B | $30.26 | $32.00 | +5.8% | Hold | 13.5x | 22 |
 GMEDGlobus Medical, Inc. | $12.1B | $89.22 | $110.67 | +24.0% | Buy | 20.0x | 36 |
 OFIXOrthofix Medical Inc. | $489M | $12.19 | $18.00 | +47.7% | Hold | — | 17 |
 AORTArtivion, Inc. | $1.7B | $34.70 | $52.00 | +49.9% | Buy | 96.8x | 12 |
Upside Potential Comparison
NVCRATRCINVAAORTOFIXGMEDZBHSNNSee ENOV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ENOV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ENOV vs SPIR
Side-by-side business, growth, and profitability comparison vs Spire Global, Inc..
Start ComparisonENOV — Frequently Asked Questions
Quick answers to the most common questions about buying ENOV stock.
What is the ENOV stock price target for 2026?
The consensus Wall Street price target for ENOV is $46.6, representing 87.5% upside from the current price of $24.85. With 13 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is ENOV a buy, sell, or hold?
ENOV has a consensus rating of "Buy" based on 13 Wall Street analysts. The rating breakdown is predominantly bullish, with 10 Buy/Strong Buy ratings. The consensus 12-month price target of $46.6 implies 87.5% upside from current levels.
Is ENOV stock overvalued or undervalued?
With a forward P/E of 6.9359x, ENOV trades at a relatively low valuation. The consensus target of $46.6 implies 87.5% appreciation, suggesting meaningful undervaluation.
How high can ENOV stock go?
The most bullish Wall Street analyst has a price target of $52 for ENOV, while the most conservative target is $40. The consensus of $46.6 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover ENOV stock?
ENOV is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 10 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the ENOV stock forecast?
The 12-month ENOV stock forecast based on 13 Wall Street analysts shows a consensus price target of $46.6, with estimates ranging from $40 (bear case) to $52 (bull case). The median consensus rating is "Buy".
What is ENOV's forward P/E ratio?
ENOV trades at a forward P/E ratio of 6.9x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy ENOV stock?
Wall Street analysts are very optimistic on ENOV, with a "Buy" consensus rating and $46.6 price target (87.5% upside). 10 of 13 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do ENOV price targets vary so much?
ENOV analyst price targets range from $40 to $52, a 26% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $46.6 consensus represents the middle ground.